deltatrials
Completed PHASE3 NCT00147264

Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial

A Randomized, Double Blind, 2X2 Factorial Design Study to Evaluate the Effects of Telmisartan vs Placebo, and of a Low-Glycemic Diet vs Control Diet, in Reducing Intra-Myocellular Lipids In Individuals With Abdominal Obesity

Sponsor: Boehringer Ingelheim

Conditions Metabolic Syndrome X
Interventions Low-Glycemic Index Diet vs. Control Diet Telmisartan (Micardis®) vs. Placebo
Updated 5 times since 2017 Last updated: Dec 13, 2016 Started: Apr 30, 2004 Primary completion: Jan 31, 2006 Completion: Nov 30, 2006

This PHASE3 trial investigates Metabolic Syndrome X and is currently completed. Boehringer Ingelheim leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
  • Canadian Institutes of Health Research (CIHR)
  • Heart and Stroke Foundation of Canada
  • McMaster University
  • Medtronic
Data source: McMaster University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Hamilton, Canada